{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009147","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.358253+00:00","generated_at":"2026-06-06T12:50:17.052260+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress","bullets":["$25M payment received Jan 30, 2024, under global licensing agreement with BMS.","Triggered by dosing of first patient in phase 2 dose expansion of CA115-001 trial of BMS-986442.","This is the second development milestone under the agreement; first achieved previously.","Payment was received on January 30, 2024, as confirmed by the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009147","json":"https://secwatch.observer/filing/0000950170-24-009147.json","markdown":"https://secwatch.observer/filing/0000950170-24-009147.md","text":"https://secwatch.observer/filing/0000950170-24-009147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024009147/0000950170-24-009147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024009147/agen-20240130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T12:50:17.052260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}